MAS1 and metabolic dysfunction-associated steatotic liver disease: Taken together, the above studies demonstrate the essential participation of the RAS in NAFLD, indicating that inhibiting the ACE/AngII/AT1R axis or activating the ACE2/Ang1-7/Mas axis may represent effective targets for NAFLD treatment.